Abiopharma

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Nutex Health Inc. (NUTX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Cytokinetics to Announce Second Quarter Results On August 7, 2025

ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

Securities Fraud Investigation Into Nutex Health Inc. (NUTX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Law Offices of Howard G. Smith Encourages Neogen Corporation (NEOG) Investors To Inquire About Securities Fraud Class Action